Nanobiotix (NBTX) announced that the FDA issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for the treatment of patients with stage 3, unresectable non-small cell lung cancer. An IND to support this trial was submitted by the global trial sponsor, Johnson & Johnson Enterprise Innovation Inc., a Johnson & Johnson (JNJ) company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBTX:
- NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
- Nanobiotix’s Revenue at Risk: The High Stakes of Sole Dependence on Janssen Partnership
- Nanobiotix Sa ADR Reports Promising 2023 Progress
- NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
- Nanobiotix Sa ADR Sets Q4 and Full Year Results Date